HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer

Peter Gichangi, Job Bwayo, Benson Estambale, Khama Rogo, Eliud Njuguna, Shadrack Ojwang, Marleen Temmerman

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)


Objective. To determine the impact of HIV infection on acute morbidity and pelvic tumor control following external beam radiotherapy (EBRT) for cervical cancer. Method. 218 patients receiving EBRT who also had HIV testing after informed consent was obtained were evaluated. Acute treatment toxicity was documented weekly during treatment and 1 month post-EBRT. Pelvic tumor control was documented at 4 and 7 months post-EBRT. Clinicians were blinded for HIV results. Results. About 20% of the patients were HIV-positive. Overall, 53.4% of the patients had radiation-related acute toxicity (grade 3-4). HIV infection was associated with a 7-fold higher risk of multisystem toxicity: skin, gastrointestinal tract (GIT) and genitourinary tract (GUT) systems. It was also an independent risk factor for treatment interruptions (adjusted relative risk 2.2). About 19% of the patients had residual tumor at 4 and 7 months post-EBRT. HIV infection was independently and significantly associated with 6-fold higher risk of residual tumor post-EBRT. The hazard ratio of having residual tumor after initial EBRT was 3.1-times larger for HIV-positive than for HIV-negative patients (P = 0.014). Conclusion. HIV is associated with increased risk of multisystem radiation-related toxicity; treatment interruptions and pelvic failure (residual tumor) following EBRT. HIV infection is an adverse prognostic factor for outcome of cervical cancer treatment.

Original languageEnglish
Pages (from-to)405-411
Number of pages7
JournalGynecologic Oncology
Issue number2
Publication statusPublished - Feb 2006
Externally publishedYes


  • Cervical cancer
  • HIV
  • Outcome
  • Radiotherapy


Dive into the research topics of 'HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer'. Together they form a unique fingerprint.

Cite this